Last reviewed · How we verify
SHR-8068 injection
SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses.
SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | SHR-8068 injection |
|---|---|
| Also known as | Anti-CTLA4 monoclonal antibody |
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SHR-8068 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the interaction between PD-L1 and its receptors (PD-1 and B7-1). This blockade releases the brakes on T-cell mediated anti-tumor immunity, allowing cytotoxic T lymphocytes to recognize and eliminate cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (PHASE2)
- A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (PHASE2)
- A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (PHASE3)
- A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (PHASE2)
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (PHASE1, PHASE2)
- Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (PHASE2)
- SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (PHASE1, PHASE2)
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |